TY - JOUR
T1 - Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage
T2 - a systematic review and meta-analysis of individual patient data
AU - VISTA-ICH Collaboration
AU - ICH Growth Individual Patient Data Meta-analysis Collaborators
AU - Al-Shahi Salman, Rustam
AU - Frantzias, Joseph
AU - Lee, Robert J.
AU - Lyden, Patrick D.
AU - Battey, Thomas W.K.
AU - Ayres, Alison M.
AU - Goldstein, Joshua N.
AU - Mayer, Stephan A.
AU - Steiner, Thorsten
AU - Wang, Xia
AU - Arima, Hisatomi
AU - Hasegawa, Hitoshi
AU - Oishi, Makoto
AU - Godoy, Daniel A.
AU - Masotti, Luca
AU - Dowlatshahi, Dar
AU - Rodriguez-Luna, David
AU - Molina, Carlos A.
AU - Jang, Dong Kyu
AU - Davalos, Antonio
AU - Castillo, José
AU - Yao, Xiaoying
AU - Claassen, Jan
AU - Volbers, Bastian
AU - Kazui, Seiji
AU - Okada, Yasushi
AU - Fujimoto, Shigeru
AU - Toyoda, Kazunori
AU - Li, Qi
AU - Khoury, Jane
AU - Delgado, Pilar
AU - SabÃn, José Ãlvarez
AU - Hernández-Guillamon, Mar
AU - Prats-Sánchez, Luis
AU - Cai, Chunyan
AU - Kate, Mahesh P.
AU - McCourt, Rebecca
AU - Venkatasubramanian, Chitra
AU - Diringer, Michael N.
AU - Ikeda, Yukio
AU - Worthmann, Hans
AU - Ziai, Wendy C.
AU - d'Esterre, Christopher D.
AU - Aviv, Richard I.
AU - Raab, Peter
AU - Murai, Yasuo
AU - Zazulia, Allyson R.
AU - Butcher, Kenneth S.
AU - Seyedsaadat, Seyed Mohammad
AU - Grotta, James C.
N1 - Funding Information:
This study was funded by the UK Medical Research Council (senior clinical fellowship G1002605 and the Edinburgh Hub for Trials Methodology Research G0800803) and the British Heart Foundation (travel fellowship FS/13/72/30531).
Funding Information:
RJL reports grants from the UK Medical Research Council, during the conduct of the study. JNG reports personal fees from CSL Behring and Octapharma; and grants from Pfizer, Boehringer Ingelheim, and Portola, outside of the submitted work. HA reports personal fees from Asuka, Bayer, Daiichi-Sankyo, and Takeda, outside of the submitted work. JCl reports grants from the DANA Foundation and personal fees from SAGE Therapeutics, outside of the submitted work. BV reports personal fees from Pfizer/Bristol-Myers Squibb and Bayer, outside of the submitted work. JK reports grants from the National Institutes of Health/National Institute of Neurological Disorders and Stroke, during the conduct of the study. CV reports grants from the Neurocritical Care Society, during the conduct of the study. MS reports grants from National Institutes of Health/National Institute of Neurological Disorders and Stroke and the American Heart Association, outside of the submitted work. CSA reports grants from the National Health and Medical Research Council of Australia, during the conduct of the study; and personal fees from Takeda and Amgen, outside of the submitted work. JR reports grants from the National Institutes of Health and personal fees from Boehringer Ingelheim and Pfizer, outside of the submitted work. All remaining authors declare no competing interests.
Publisher Copyright:
© 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Background: Intracerebral haemorrhage growth is associated with poor clinical outcome and is a therapeutic target for improving outcome. We aimed to determine the absolute risk and predictors of intracerebral haemorrhage growth, develop and validate prediction models, and evaluate the added value of CT angiography. Methods: In a systematic review of OVID MEDLINE—with additional hand-searching of relevant studies' bibliographies— from Jan 1, 1970, to Dec 31, 2015, we identified observational cohorts and randomised trials with repeat scanning protocols that included at least ten patients with acute intracerebral haemorrhage. We sought individual patient-level data from corresponding authors for patients aged 18 years or older with data available from brain imaging initially done 0·5–24 h and repeated fewer than 6 days after symptom onset, who had baseline intracerebral haemorrhage volume of less than 150 mL, and did not undergo acute treatment that might reduce intracerebral haemorrhage volume. We estimated the absolute risk and predictors of the primary outcome of intracerebral haemorrhage growth (defined as >6 mL increase in intracerebral haemorrhage volume on repeat imaging) using multivariable logistic regression models in development and validation cohorts in four subgroups of patients, using a hierarchical approach: patients not taking anticoagulant therapy at intracerebral haemorrhage onset (who constituted the largest subgroup), patients taking anticoagulant therapy at intracerebral haemorrhage onset, patients from cohorts that included at least some patients taking anticoagulant therapy at intracerebral haemorrhage onset, and patients for whom both information about anticoagulant therapy at intracerebral haemorrhage onset and spot sign on acute CT angiography were known. Findings: Of 4191 studies identified, 77 were eligible for inclusion. Overall, 36 (47%) cohorts provided data on 5435 eligible patients. 5076 of these patients were not taking anticoagulant therapy at symptom onset (median age 67 years, IQR 56–76), of whom 1009 (20%) had intracerebral haemorrhage growth. Multivariable models of patients with data on antiplatelet therapy use, data on anticoagulant therapy use, and assessment of CT angiography spot sign at symptom onset showed that time from symptom onset to baseline imaging (odds ratio 0·50, 95% CI 0·36–0·70; p<0·0001), intracerebral haemorrhage volume on baseline imaging (7·18, 4·46–11·60; p<0·0001), antiplatelet use (1·68, 1·06–2·66; p=0·026), and anticoagulant use (3·48, 1·96–6·16; p<0·0001) were independent predictors of intracerebral haemorrhage growth (C-index 0·78, 95% CI 0·75–0·82). Addition of CT angiography spot sign (odds ratio 4·46, 95% CI 2·95–6·75; p<0·0001) to the model increased the C-index by 0·05 (95% CI 0·03–0·07). Interpretation: In this large patient-level meta-analysis, models using four or five predictors had acceptable to good discrimination. These models could inform the location and frequency of observations on patients in clinical practice, explain treatment effects in prior randomised trials, and guide the design of future trials. Funding: UK Medical Research Council and British Heart Foundation.
AB - Background: Intracerebral haemorrhage growth is associated with poor clinical outcome and is a therapeutic target for improving outcome. We aimed to determine the absolute risk and predictors of intracerebral haemorrhage growth, develop and validate prediction models, and evaluate the added value of CT angiography. Methods: In a systematic review of OVID MEDLINE—with additional hand-searching of relevant studies' bibliographies— from Jan 1, 1970, to Dec 31, 2015, we identified observational cohorts and randomised trials with repeat scanning protocols that included at least ten patients with acute intracerebral haemorrhage. We sought individual patient-level data from corresponding authors for patients aged 18 years or older with data available from brain imaging initially done 0·5–24 h and repeated fewer than 6 days after symptom onset, who had baseline intracerebral haemorrhage volume of less than 150 mL, and did not undergo acute treatment that might reduce intracerebral haemorrhage volume. We estimated the absolute risk and predictors of the primary outcome of intracerebral haemorrhage growth (defined as >6 mL increase in intracerebral haemorrhage volume on repeat imaging) using multivariable logistic regression models in development and validation cohorts in four subgroups of patients, using a hierarchical approach: patients not taking anticoagulant therapy at intracerebral haemorrhage onset (who constituted the largest subgroup), patients taking anticoagulant therapy at intracerebral haemorrhage onset, patients from cohorts that included at least some patients taking anticoagulant therapy at intracerebral haemorrhage onset, and patients for whom both information about anticoagulant therapy at intracerebral haemorrhage onset and spot sign on acute CT angiography were known. Findings: Of 4191 studies identified, 77 were eligible for inclusion. Overall, 36 (47%) cohorts provided data on 5435 eligible patients. 5076 of these patients were not taking anticoagulant therapy at symptom onset (median age 67 years, IQR 56–76), of whom 1009 (20%) had intracerebral haemorrhage growth. Multivariable models of patients with data on antiplatelet therapy use, data on anticoagulant therapy use, and assessment of CT angiography spot sign at symptom onset showed that time from symptom onset to baseline imaging (odds ratio 0·50, 95% CI 0·36–0·70; p<0·0001), intracerebral haemorrhage volume on baseline imaging (7·18, 4·46–11·60; p<0·0001), antiplatelet use (1·68, 1·06–2·66; p=0·026), and anticoagulant use (3·48, 1·96–6·16; p<0·0001) were independent predictors of intracerebral haemorrhage growth (C-index 0·78, 95% CI 0·75–0·82). Addition of CT angiography spot sign (odds ratio 4·46, 95% CI 2·95–6·75; p<0·0001) to the model increased the C-index by 0·05 (95% CI 0·03–0·07). Interpretation: In this large patient-level meta-analysis, models using four or five predictors had acceptable to good discrimination. These models could inform the location and frequency of observations on patients in clinical practice, explain treatment effects in prior randomised trials, and guide the design of future trials. Funding: UK Medical Research Council and British Heart Foundation.
UR - http://www.scopus.com/inward/record.url?scp=85054090975&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(18)30253-9
DO - 10.1016/S1474-4422(18)30253-9
M3 - Article
C2 - 30120039
AN - SCOPUS:85054090975
SN - 1474-4422
VL - 17
SP - 885
EP - 894
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 10
ER -